Form 4: Catalyst Pharmaceuticals Director Acquires Shares Through Restricted Stock Unit Vesting

Director David S. Tierney acquired 4,000 shares of Catalyst Pharmaceuticals common stock on February 14, 2025, through the vesting of restricted stock units.

Summary

• On February 14, 2025, David S. Tierney, a director of Catalyst Pharmaceuticals, acquired 4,000 shares of common stock.
• This acquisition resulted from the vesting of restricted stock units (RSUs).
• The RSUs vested in three equal tranches: February 14, 2023, February 14, 2024, and February 14, 2025.
• Following the transaction, Tierney directly owns 355,620 shares of Catalyst Pharmaceuticals.
• Tierney also owns 208,274 derivative securities in the form of restricted stock units.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to insider transactions, which is neither inherently positive nor negative. It simply reflects the execution of a pre-existing compensation plan.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the holdings and transactions of company insiders, allowing investors to monitor their activity.

Stakeholder Impact

• The transaction has a minor impact on shareholders as it increases the number of outstanding shares, but it's unlikely to be significant.

Key Dates